This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

This study has been completed.
Sponsor:
Collaborator:
Guangdong Provincial Institute of Biological Products And Materia Medica
Information provided by (Responsible Party):
Changchun Keygen Biological Products Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01815073
First received: March 18, 2013
Last updated: February 20, 2014
Last verified: February 2014
  Purpose
The purpose of this study is to observe the occurrence of adverse events and seroconversion rate, geometric mean titres (GMTs) of live attenuated varicella vaccine,live attenuated JE vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine, respectively.

Condition Intervention Phase
Japanese Encephalitis Chickenpox Biological: Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine Biological: Live Attenuated Varicella Vaccine Biological: live attenuated JE vaccine Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

Resource links provided by NLM:


Further study details as provided by Changchun Keygen Biological Products Co., Ltd.:

Primary Outcome Measures:
  • Seroconversion rate and GMTs for live attenuated varicella vaccine, live attenuated JE vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine, respectively. [ Time Frame: 35-42 days after vaccination ]

Secondary Outcome Measures:
  • Occurrence of adverse events. [ Time Frame: within 30 days after each vaccination ]

Enrollment: 497
Study Start Date: March 2013
Study Completion Date: July 2013
Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine
use the left arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
Biological: Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine
Experimental: Live Attenuated Varicella Vaccine
use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
Biological: Live Attenuated Varicella Vaccine
Experimental: Live Attenuated JE Vaccine
use the right arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
Biological: live attenuated JE vaccine

  Eligibility

Ages Eligible for Study:   1 Year to 3 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
  • Participant is aged ≥ 1 year to ≤ 3 years
  • Participant without previous history of chickenpox, zoster and epidemic encephalitis B
  • Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures
  • Body temperature ≤ 37.5℃

Exclusion Criteria:

  • Known allergy to any constituent of the vaccine
  • Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever
  • Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
  • Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
  • Failed to the Expanded Programme on Immunization(EPI)
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination
  • Plan to receive any vaccine in the 4 weeks following the trial vaccination
  • Known bleeding disorder
  • Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the trial vaccination
  • Reported the history of acute illness had need systemic antibiotics or anti-viral treatment of infections in the 7 days preceding the trial vaccination
  • An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial
  • Participation in any other interventional clinical trial
  • Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01815073

Locations
China, Guangdong
Guangzhou Haizhu District Center for Disease Control and Prevention
Guangzhou, Guangdong, China
Sponsors and Collaborators
Changchun Keygen Biological Products Co., Ltd.
Guangdong Provincial Institute of Biological Products And Materia Medica
Investigators
Principal Investigator: Zheng Huizhen, Master Guangdong Center for Disease Prevention and Control
  More Information

Responsible Party: Changchun Keygen Biological Products Co., Ltd.
ClinicalTrials.gov Identifier: NCT01815073     History of Changes
Study First Received: March 18, 2013
Last Updated: February 20, 2014

Additional relevant MeSH terms:
Chickenpox
Encephalitis
Encephalitis, Japanese
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Encephalitis, Arbovirus
Arbovirus Infections
Encephalitis, Viral
Central Nervous System Viral Diseases
RNA Virus Infections
Flavivirus Infections
Flaviviridae Infections
Infectious Encephalitis
Central Nervous System Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 27, 2017